Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients.
The clinical reaction and the immunological response to influenza virus vaccine were studied in 43 B-cell chronic lymphocytic leukaemia patients. The Vaxigrip vaccine was administered containing the antigens A/Ghizhou/54/89, A/Singapore/6/86, and B/Yamagata/16/88. The side-effects observed were minimal and well tolerated. Antibody production with titres > 1:20 on day 15 was observed at least for one antigen in 35 patients (81%). In 23 of them (63%) this response was retained on days 30 and 60. Patients with IgG levels (< 700 mg/dl) responded less well as compared to those having normal IgG levels (> 700 mg/dl).
Gribabis
D A
DA
First Department of Medicine, National and Kapodistrian University, School of Medicine, Laikon General Hospital, Athens, Greece.
Panayiotidis
P
P
Boussiotis
V A
VA
Hannoun
C
C
Pangalis
G A
GA
D000328:Adult; D000368:Aged; D000917:Antibody Formation; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D006969:Hypersensitivity, Immediate / Q000209:etiology; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D014611:Vaccination
D007252:Influenza Vaccines